Literature DB >> 8220158

A comparative analysis of alkylating agent and epipodophyllotoxin-related leukemias.

M Ellis1, M Ravid, M Lishner.   

Abstract

This review deals with the differences between leukemias--induced by alkylating agents as opposed to a "new form" of treatment related leukemia due to prior exposure to epipodophyllotoxins the latter having a short treatment--disease onset interval, absence of a MDS phase, a monocytic component and cytogenetic abnormalities involving the 11q23 band. The link between the existence of oncogenes or tumor suppressor genes located on the involved portion of chromosome 11 and the development of epipodophyllotoxin-related leukemia still needs to be examined. Alkylating agents--induced leukemias have a longer treatment--disease onset interval, have a prior myelodysplastic syndrome, and are most frequent myeloblastic or myelomonocytic in nature. Karyotype analysis reveals partial or complete deletion of chromosomes no. 5 or 7. This form of leukemia is highly resistant to treatment in the majority of cases. Some of the possible molecular mechanisms of leukemogenesis are discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8220158     DOI: 10.3109/10428199309054725

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  5 in total

Review 1.  Hematologic aspects of myeloablative therapy and bone marrow transplantation.

Authors:  Roger S Riley; Michael Idowu; Alden Chesney; Shawn Zhao; John McCarty; Lawrence S Lamb; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

Review 2.  Cytogenetics in acute myeloid leukemia.

Authors:  Claudia Schoch; Torsten Haferlach
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

3.  MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility.

Authors:  Nathan A Ellis; Dezheng Huo; Ozlem Yildiz; Lisa J Worrillow; Mekhala Banerjee; Michelle M Le Beau; Richard A Larson; James M Allan; Kenan Onel
Journal:  Blood       Date:  2008-04-21       Impact factor: 22.113

Review 4.  Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS).

Authors:  Peter Valent; Friedrich Wimazal; Ilse Schwarzinger; Wolfgang R Sperr; Klaus Geissler
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

5.  Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma.

Authors:  R Saso; S Kulkarni; P Mitchell; J Treleaven; G J Swansbury; J Mehta; R Powles; S Ashley; A Kuan; T Powles
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.